Efficacy of oral vs. topical, or combined oral and topical 5-aminosalicylates, in Ulcerative Colitis: systematic review and meta-analysis.
about
Pharmacological- and non-pharmacological therapeutic approaches in inflammatory bowel disease in adultsMedical Therapy of Active Ulcerative ColitisManagement of ulcerative colitisLong-term efficacy and safety of once-daily mesalazine granules for the treatment of active ulcerative colitis.Ulcerative Colitis: Update on Medical Management.Efficacy of a pH-dependent controlled-release mesalazine based on clinical and endoscopic assessment for ulcerative colitis: a retrospective cohort study.Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX(®) mesalamine.Emerging Treatment Options in Mild to Moderate Ulcerative Colitis.Alicaforsen, an antisense inhibitor of ICAM-1, as treatment for chronic refractory pouchitis after proctocolectomy: A case series.5-ASA colonic mucosal concentrations resulting from different pharmaceutical formulations in ulcerative colitis.Second Korean guidelines for the management of ulcerative colitis.Ulcerative colitis: prevention of relapse.Mesalazine for the treatment of inflammatory bowel disease.Review article: integrating budesonide-MMX into treatment algorithms for mild-to-moderate ulcerative colitis.Current and emerging maintenance therapies for ulcerative colitis.Conventional drug therapy for inflammatory bowel disease.Inflammatory bowel disease meta-evidence and its challenges: is it time to restructure surgical research?Therapeutic Manipulation of the Microbiome in IBD: Current Results and Future Approaches.Ulcerative Colitis: What is the Optimal Treatment Goal and How Do We Achieve It?New treatment strategies for ulcerative colitis.Optimizing pharmacologic management of inflammatory bowel disease.Tripeptide K(D)PT Is Well Tolerated in Mild-to-moderate Ulcerative Colitis: Results from a Randomized Multicenter Study.Reviewing treatments and outcomes in the evolving landscape of ulcerative colitis.MMX® technology and its applications in gastrointestinal diseases.Emerging oral targeted therapies in inflammatory bowel diseases: opportunities and challengesAlicaforsen in the treatment of pouchitis.Evidence-based clinical practice guidelines for inflammatory bowel disease.Inhibition of matrix metalloproteinase-9 by a barbiturate-nitrate hybrid ameliorates dextran sulphate sodium-induced colitis: effect on inflammation-related genes.Inducing remission of ulcerative colitis: are clinicians better equipped than ever?Sustained Clinical Efficacy and Mucosal Healing of Thiopurine Maintenance Treatment in Ulcerative Colitis: A Real-Life Study
P2860
Q26768280-AD318198-48A2-4421-BD99-21B763DC45D8Q26777729-4B3CEDDD-2BC5-4DEB-A393-F8997B803E7EQ26778250-6317F70C-39A2-4321-AEF5-6496F83F632BQ34273329-EABA83A1-9654-4F81-B847-9950A4CEF82DQ35781294-BCE9DDDD-42EC-4EA5-8780-89A7812F0BD7Q35928671-BE516E4F-FA54-4FF1-932B-966C35D91EB7Q36144377-1662F153-F0E4-4B14-85C0-5A694B1B59DDQ36172156-62791B8F-28AE-4748-8540-822DA17A8BA1Q36616115-F8B361D6-2A74-4E17-A725-A155151BD467Q37162453-F98C5E34-58E8-4AB5-A5D2-87AEFB4C47D2Q37662503-722DF2F4-3461-4748-B966-ACB1777E1C7EQ38103628-E36BC299-B593-4C8A-875C-BDBC482527C7Q38114476-06F8C59B-96E8-484F-88D0-7B2C8AE97419Q38196945-8E195F25-12BD-43A0-BF92-3C34B9600676Q38197719-CD0D9CF1-BF38-4DAF-8523-CD67094AEAF0Q38293796-444868CF-509C-45E9-9FA4-DDEEC6BB6995Q38302725-85CE4C0D-89A7-4A17-B31A-C31332B41054Q38321531-905F5DCD-E49B-4AFB-8138-78FF11C291D5Q38331566-28868713-3593-488B-BEE3-B9F9FD5732B8Q38670811-D56FD81C-9F31-4207-8D41-5DA6C4324D93Q38687407-3373F0C7-3E1D-4271-A83E-E528F3809B96Q39018440-864219A2-8574-4D84-89E0-D84A276EBA31Q39251794-A00EEEC3-C04C-4334-AEDF-994F70EBD630Q40095211-75B3606F-7870-491A-9ED2-C9A64CE4E741Q42375646-D5F6B1CF-C4AB-4D24-9C7E-969875230B37Q48567953-60657AB5-6EE2-4370-822A-B9F320876C9CQ50079201-CD01E5C4-9856-4416-A811-F8A5F6A6EA8EQ51197180-C3D9D0ED-A02C-45DC-A68E-A886316ABEEDQ57707316-8E3E1C9D-E157-4D75-A0A1-F92734BB2000Q58585367-87141A21-9F3D-4D81-AF92-8053BC79DE1B
P2860
Efficacy of oral vs. topical, or combined oral and topical 5-aminosalicylates, in Ulcerative Colitis: systematic review and meta-analysis.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Efficacy of oral vs. topical, ...... atic review and meta-analysis.
@en
Efficacy of oral vs. topical, ...... atic review and meta-analysis.
@en-gb
Efficacy of oral vs. topical, ...... atic review and meta-analysis.
@nl
type
label
Efficacy of oral vs. topical, ...... atic review and meta-analysis.
@en
Efficacy of oral vs. topical, ...... atic review and meta-analysis.
@en-gb
Efficacy of oral vs. topical, ...... atic review and meta-analysis.
@nl
prefLabel
Efficacy of oral vs. topical, ...... atic review and meta-analysis.
@en
Efficacy of oral vs. topical, ...... atic review and meta-analysis.
@en-gb
Efficacy of oral vs. topical, ...... atic review and meta-analysis.
@nl
P2860
P356
P1476
Efficacy of oral vs. topical, ...... atic review and meta-analysis.
@en
P2093
Jean-Paul Achkar
Khurram J Khan
P2860
P304
167-76; author reply 177
P356
10.1038/AJG.2011.410
P407
P577
2011-11-22T00:00:00Z